Sunday, November 24, 2024
11/24/2024
PROJECT SUMMARY Craniofacial developmental disorders such as cleft palate and retrognathia (smaller lower jaw) often arise due to defects in neural crest cell development and affect 1 in 700 and 1 in 1,500 live human births, respectively. Cleft palate and retrognathia often present with other craniofacial anomalies in conditions such as Treacher Collins syndrome and DiGeorge syndrome. Although genetic analyses have identified the genes responsible for some craniofacial anomalies, the vast majority have an undiagnosed molecular etiology and cellular pathogenesis. In an ENU mutagenesis screen, the Med23 gene was identified to be critical for craniofacial development. A point mutation in Med23 results in craniofacial and vascular defects, leading to embryonic lethality at mid-gestation. Med23 belongs to the tail module of the Mediator complex, which is a global transcription coregulator for genes transcribed by RNA Polymerase II. Med23 is ubiquitously expressed in mouse embryos, thereby, raising an important question of how a ubiquitously expressed protein regulates tissue specific development during embryogenesis, particularly in craniofacial development. To understand the function of Med23 in craniofacial and neural crest cell development, I generated neural crest cell specific conditional knockouts of Med23 that exhibit cleft palate, retrognathia, glossoptosis and cleidocranial dysplasia. Interestingly, endothelial cell specific conditional knockouts of Med23 also result in craniofacial defects together with vascular defects. In this proposal, I will test the overarching hypothesis that Med23 and other tail module subunits of Mediator have important and distinct transcriptional regulatory functions in craniofacial development via the control of neural crest cell and endothelial cell transcriptomes. Specifically, I will address the following aims. (Aim 1) Identify the molecular mechanism underlying the craniofacial defect in neural crest cell specific mutants of Med23 by analyzing transcriptomic changes in these mutants as well as by identifying Med23 DNA and protein binding partners. (Aim 2) Characterize the pathogenesis of craniofacial defects in endothelial cell specific mutants of Med23 and their underlying molecular mechanisms by analysis of the craniofacial transcriptome. Furthermore, I will test the mechanism of Med23-mediated control of key regulatory genes that function in craniofacial development and are linked to craniofacial disorders. Specifically, I will investigate the molecular basis of Med23 function via its control of Runx2 and β-Catenin in the mandibular mesenchyme. (Aim 3) Generate and characterize loss of function mutants of the Mediator tail submodule protein, Med24. The broad impact of this innovative proposal will advance our mechanistic understanding of the gene and protein networks underlying the function of global transcription co-factor Mediator complex proteins in fundamental cellular processes and development.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
